Scrip (Citeline) surveyed approximately 50 industry leaders for its annual “Scrip Asks” series — selected from over 330 submissions across the biopharma sector. Ali Pashazadeh, CEO of Treehill Partners, was among the voices featured in Part 1, which examines the forces shaping capital allocation and dealmaking in 2026.
Contributing to the section on investment criteria and asset selection, Ali highlighted the growing emphasis on accountability throughout the development process: “We are now seeing evidence of innovative and novel financing obtaining dividends, and we expect this to continue through 2026, but only for those that can demonstrate properly considered investable proposals, with long-term development and manufacturing strategies leading to a commercially viable product. Specifically, the greater degree of accountability and ownership being asked not only of management but also service providers to ensure optimal trial design and trial execution will further increase.”
The article explores six dimensions of capital allocation shaping 2026, including M&A deal volume predictions, buyer evolution, cross-border dealmaking, sector-specific trends, innovative financing structures, and investment criteria. Contributors include leaders from L.E.K. Consulting, 4BIO Capital, Astellas Pharma, Daiichi Sankyo, CSL, Cooley, Syncona, and many others, addressing themes from the $300bn patent cliff driving deal urgency to the emergence of midsize pharma as aggressive acquirers and China’s growing role as a source of novel assets.
Read the full article: https://insights.citeline.com/scrip/scrip-asks/scrip-asks-what-does-2026-hold-for-biopharma-part-1-capital-allocation-and-dealmaking-U3B4EUN3GZGNXM6QI3ZGXVMNZY/
📌 Treehill Partners – helping biopharma companies optimize development strategies for both regulatory approval and commercial success, unlocking transaction optionality with strategic and financial players.